- Home
- BLRX vs MBRX Comparison
BLRX vs MBRX Comparison
Compare BLRX & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- MBRX
- Stock Information
- Founded
- BLRX 2003
- MBRX 2015
- Country
- BLRX Israel
- MBRX United States
- Employees
- BLRX N/A
- MBRX N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- MBRX Health Care
- Exchange
- BLRX Nasdaq
- MBRX Nasdaq
- Market Cap
- BLRX 10.3M
- MBRX 11.3M
- IPO Year
- BLRX 2011
- MBRX 2016
- Fundamental
- Price
- BLRX $2.93
- MBRX $1.10
- Analyst Decision
- BLRX Buy
- MBRX Strong Buy
- Analyst Count
- BLRX 2
- MBRX 2
- Target Price
- BLRX $26.00
- MBRX $6.00
- AVG Volume (30 Days)
- BLRX 30.2K
- MBRX 349.3K
- Earning Date
- BLRX 05-27-2025
- MBRX 05-09-2025
- Dividend Yield
- BLRX N/A
- MBRX N/A
- EPS Growth
- BLRX N/A
- MBRX N/A
- EPS
- BLRX N/A
- MBRX N/A
- Revenue
- BLRX $28,940,000.00
- MBRX N/A
- Revenue This Year
- BLRX N/A
- MBRX N/A
- Revenue Next Year
- BLRX N/A
- MBRX N/A
- P/E Ratio
- BLRX N/A
- MBRX N/A
- Revenue Growth
- BLRX 502.92
- MBRX N/A
- 52 Week Low
- BLRX $2.30
- MBRX $0.40
- 52 Week High
- BLRX $35.60
- MBRX $5.47
- Technical
- Relative Strength Index (RSI)
- BLRX 48.07
- MBRX 56.62
- Support Level
- BLRX $2.30
- MBRX $0.80
- Resistance Level
- BLRX $3.09
- MBRX $1.10
- Average True Range (ATR)
- BLRX 0.22
- MBRX 0.10
- MACD
- BLRX 0.06
- MBRX 0.04
- Stochastic Oscillator
- BLRX 79.33
- MBRX 92.77
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.